Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
S. Z. Usmani, J. D. Cavenagh, A. R. Belch, C. Hulin, S. Basu, D. White, A. Nooka, A. Ervin-Haynes, W. Yiu, Y. Nagarwala, A. Berger, C. G. Pelligra, S. Guo, G. Binder, C. J. Gibson, T. Facon
Dive into the research topics of 'Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma'. Together they form a unique fingerprint.